

Equine coital exanthema (ECE) caused by equid alphaherpesvirus 3 (EHV3), is a venereal, highly contagious disease that is characterized by the development of pock-like eruptions, vesicles, pustules and ulcers on the external genital organs of mares and stallions.

The infection does not usually result in systemic illness, and neither infertility nor abortion. However, the **negative impact on the equine breeding industry** is the temporary disruption of mating activities; the risk of EHV3 dissemination, and the risk of outbreaks in artificial insemination (AI) and embryo transfer (ET) centers.

The equine virus laboratory of the CNIA-INTA Virology Institute has formulated and developed a specific topical antiviral product to treat ECE that shortens recovery time and reduces viral load, while controlling contagion and outbreaks among animals.

ADVANTAGES:

- Topical, easy-to-apply product.
- Proven in EHV3-infected mares.
- Preventive and therapeutic use.
- National development with industrial scaling feasibility and global scope.

TECHNOLOGY READINESS LEVEL: MIDDLE. Laboratory scale product prototype. Functionality tests on infected animals completed. Technology available for licensing and requires investment for scaling and marketing.

INTELLECTUAL PROPERTY RIGHTS STATUS: Formula and development qualify for trade secrecy protection.

DNA de Vinculación Tecnológica y Relaciones Institucionales - National Coordination Office for Technological Cooperation and Institutional Relations, INTA . Intellectual Property Department-Technological Antenna5- Dr. Mariana Nanni nanni.mariana@inta.gob.ar

